Table 2. Demographic information for included studies with ZNF217 expression.

Reference	Country	Cancer type	No.	Mean age (y)	Male/Female	TNM stage	Median follow-up (m)	ZNF217 (−/+)	Subcellular localization	NOS score
Frietze et al 2014 [22]	USA	Breast cancer	319	NA	All female	I–IV	NA	160/159	Nucleus	7
Li et al 2014 [23]	China	Ovarian cancer	44	48.9	All female	I–IV	60	18/26	Nucleus	8
Li et al 2015 [24]	China	Colon cancer	82	57.4	42/40	I–IV	NA	27/55	Cytoplasm	7
Littlepage et al 2012 [25]	USA	Breast cancer	118	NA	All female	I–IV	0–144	59/59	Nucleus	7
Mao et al 2011 [26]	China	Glioblastoma	84	49.6 ± 5.7	46/38	II–III	NA	62/22	Nucleus	7
Nguyen et al 2014 [27]	France	Breast cancer	97	48.5	All female	NA	84	45/52	Nucleus and cytoplasm	8
Rahman et al 2012 [28]	Japan	Ovarian cancer	60	54.0	All female	I–IV	NA	40/20	Nucleus	6
Rooney et al 2004 [29]	UK	Colon cancer	100	69.0	56/44	I–III	54 (1–96)	43/57	Nucleus	7
Vendrell et al 2012 [30]	France	Breast cancer	78	55.8 ± 7.6	All female	I–IV	87 (2–169)	32/46	Nucleus	8

No.: number; y: year; m: month; NA: not available; NOS: Newcastle-Ottawa Scale.